Microfluidic Chip Models Breast Tumor Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for studying cancer metastasis lack physiologically relevant tumor microenvironments, limiting the effectiveness of therapeutic strategies and the ability to independently assess the effects of microenvironmental cues on cancer cell behavior.
Innovation Solution
A microfluidic device is developed using hydrogel-based biomaterials and microengineering technology to create a three-dimensional, vascularized human breast tumor microenvironment that includes cancer cells, stromal cells, and endothelial cells, allowing for controlled studies of cancer cell migration and drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If 2D rigid substrates and Boyden chambers are used for in vitro cell migration studies, then high throughput and economic efficiency are achieved, but the physiological relevance of the tumor microenvironment is lost
Solution Approach 1:
The patent transitions from 2D rigid substrates to 3D hydrogel matrices, adding a dimensional aspect that better recapitulates the native tumor microenvironment. The 3D architecture allows cells to migrate through a matrix that mimics the extracellular matrix structure, providing both physiological relevance and maintaining microfluidic high-throughput capabilities.
Solution Approach 2:
The patent employs composite hydrogel materials that combine multiple properties: structural support from the hydrogel network, biochemical cues from embedded matrix proteins, and mechanical properties that mimic native tissue. This composite approach enables physiological relevance while maintaining the controlled environment needed for high-throughput screening.
2Reliability
If 3D macroscale ECM hydrogels are used to study cancer metastasis, then physiological relevance is improved, but precise control over cellular distribution and vascularity is lost
Solution Approach 1:
The patent segments the tumor microenvironment into distinct functional zones within the microfluidic device: tumor cell regions, stromal cell regions, and endothelial cell regions. Each zone can be independently populated with specific cell types and subjected to different experimental conditions, enabling precise control over cellular distribution while maintaining 3D physiological relevance.
Solution Approach 2:
The patent introduces microfluidic channels as intermediaries that connect different cellular compartments and enable controlled delivery of nutrients, growth factors, and therapeutic agents. These channels mediate the interaction between different cell populations and allow precise spatial and temporal control over the microenvironment.
3Measurement precision
If genetically modified animal models are used to study cancer metastasis, then molecular basis of disease progression is defined, but the ability to independently study microenvironmental cues is reduced and cost increases
Solution Approach 1:
The patent extracts the essential components of the tumor microenvironment (cancer cells, stromal cells, endothelial cells, and ECM) and reconstitutes them in a controlled in vitro setting. This extraction allows independent manipulation of each component to study their specific contributions to metastasis without the confounding variables present in whole animal models.
Solution Approach 2:
The patent creates a simplified copy of the in vivo tumor microenvironment that captures the essential biological interactions. This in vitro model copy enables systematic study of molecular mechanisms while reducing complexity and cost compared to genetically modified animal models.
Data Source
AI summary
A microfluidic device for more accurately modeling the in vitro environment in which cancer occurs is disclosed. The microfluidic device includes a surface defining one or more microfluidic channels, a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels, a second three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the first three dimensional scaffold, and that is spatially separated from the one or more microfluidic channels, and a third three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the one or more microfluidic channels and the second three dimensional scaffold. The device can be used to assay anti-cancer agents, or as a system for modeling the growth, behavior, or metastasis and tumor formation of cancer cells.